Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the long-term safety of zanubrutinib regimens in participants with B-cell malignancies who participated in a BeiGene parent study for zanubrutinib.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04170283
Study type Interventional
Source BeiGene
Contact BeiGene
Phone +1-877-828-5568
Email clinicaltrials@beigene.com
Status Recruiting
Phase Phase 3
Start date January 21, 2020
Completion date December 2028

See also
  Status Clinical Trial Phase
Completed NCT02343120 - Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Phase 1/Phase 2
Completed NCT02018861 - A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101) Phase 1/Phase 2
Terminated NCT03701438 - Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Completed NCT02327078 - A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204) Phase 1/Phase 2
Completed NCT04551963 - Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Phase 1
Recruiting NCT05683717 - A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Completed NCT01775631 - Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma Phase 1
Active, not recruiting NCT01905813 - Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies Phase 1
Recruiting NCT05275504 - Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies Phase 1
Active, not recruiting NCT02457598 - Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies Phase 1
Recruiting NCT03050190 - A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies Phase 1/Phase 2
Recruiting NCT03125577 - Combination CAR-T Cell Therapy Targeting Hematological Malignancies Phase 1/Phase 2
Recruiting NCT04509700 - Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Phase 2
Not yet recruiting NCT03642496 - Clinical Study of ET019002-T Cell Therapy for Refractory/Relapsed B-Cell Malignancies Early Phase 1
Completed NCT00983619 - A Clinical Study Using MEDI-551 in Adult Participants With Relapsed or Refractory Advanced B-Cell Malignancies Phase 1/Phase 2